This is an actual MedMen (MMEN.C) news release

When a cannabis company loses a lot of money every quarter, and has to sell real estate, cancel acquisitions, lay off staff, renegotiate existing financing to higher interest rates and offer stock to new financiers at a discount to the market price, all to stay afloat, one might expect their newsflow to show bold new moves, innovation, maybe some hard austerity decisions.

Ceylon Graphite (CYL.V) up nearly double since shift to production

No resource, no multi-million dollar raise, no problem. Ceylon Graphite (CYL.V), which has taken the unusual (in mining circles) decision to just freaking start digging, rather than go through eight years of behind-protection, triangulation, and capital raising first, is up 20% today as the first containers fill with graphite and execs chase down end user agreements. With stock selling for just $0.06 a few days ago, volume has increased and buyers are being found, leading the stock to $0.095 at the time of writing.

Equity.Guru podcast: Mistakes were made – Jeanette VanderMarel’s happy goodbye to Beleave (BE.C)

With the twitter announcement this morning that Jeanette had "happily" left the position of CEO at Beleave Kannabis (BE.C), Equity.Guru's own Chris Parry was chomping at the bit to find out just what "happily" meant for the market and investors. Twenty minutes after making her announcement, VanderMarel phoned up Chris to give him the skinny on her decision as well as some explanations for past actions which gave both industry players and investors some pause.

Falcon Gold (FG.V) is a tiny little bet on a big fat gold region

Close-ology is a mining term used to describe companies that are close to another company that is running red hot, and may justifiably make the case that they can be hot too. For some, like serial ring-staker Ryan Kalt, close-ology is a business model. The moment someone announces they've found something interesting in Dildo, Newfoundland or Punkydoodle Corners, Ontario, Kalt's crew hops on their laptops, busts out the credit card, and register claims all around it, sometimes without ever having walked the land.

Deathwatch: MedMen (MMEN.C) is cutting out everything but the cancer that is killing it

If you've been around this joint for a while, you'll have seen us arguing folks would be silly to invest in MedMen (MMEN.C) if hanging on to your money is a thing you aspire to do. That's not because we have a hate on for the dude-bros running the show, or because they're not a client, or because we're short sellers, or any of the other 50 or so reasons MedMen homers have thrown at us over the last few years as a rationale for us not seeing the company in the same rose-coloured way they do. It's because MedMen is, and has always been, shit.